ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

ClinicalTrials.gov ID: NCT06297590

Public ClinicalTrials.gov record NCT06297590. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease

Study identification

NCT ID
NCT06297590
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
48 participants

Conditions and interventions

Interventions

  • Flortaucipir F18 Drug
  • LY3954068 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2024
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027
Last update posted
Apr 19, 2026

2024 – 2027

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
K2 Medical Research, LLC Maitland Florida 32751 Recruiting
Charter Research, LLC The Villages Florida 32162 Recruiting
CenExel iResearch, LLC (CenExel iRA) Decatur Georgia 30030 Recruiting
Massachusetts General Hospital (MGH) Charlestown Massachusetts 02129 Not yet recruiting
CenExel AMRI Toms River New Jersey 08755 Recruiting
Duke University Durham North Carolina 27710 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06297590, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06297590 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →